FDA advisers recommend against Delcath’s cancer therapy

(Reuters) – A panel of advisers to the U.S. health regulator unanimously recommended against approving Delcath Systems Inc’s cancer therapy for a rare form of eye cancer that spreads to the liver, saying it was too risky. Concerns that the treatment may not win U.S. Food & Drug Administration (FDA) approval have driven New York-based Delcath’s shares down by three-quarters from a year high of $2.94 in May. The shares fell heavily on Tuesday when FDA staff documents were released that showed serious concerns about the risks of the therapy, the only product Delcath has in development. (http://r. …

Healthcare law opponents sue Obama officials over IRS rules

By Patrick Temple-West WASHINGTON (Reuters) – A group of individuals and businesses filed a lawsuit against the Obama administration’s healthcare overhaul on Thursday, hoping to stop the law in states that have not set up new insurance exchanges. The complaint filed in the Washington federal court challenges federal rules issued in 2012 for implementing the president’s 2010 healthcare law which goes into full force in January 2014. …

1 77 78 79 80 81 87